Clinical Trial Update: Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating oral Full-Spectrum Microbiota (CP101) for efficacy, safety, and tolerability in recurrent Clostridioides difficile infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• Full-Spectrum MicrobiotaTM (CP101) (CP101)

Snippet

Sponsor: Finch Research and Development LLC. | Conditions: Clostridium Difficile Infection Recurrence | Phase 2 | Status: COMPLETED | Results posted: 2022-07-06